These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

934 related items for PubMed ID: 20843542

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B, Fox KM, Watson C, Gandra SR.
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
    Chandran V, Shen H, Pollock RA, Pellett FJ, Carty A, Cook RJ, Gladman DD.
    J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
    [Abstract] [Full Text] [Related]

  • 46. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.
    Clin Exp Rheumatol; 2012 Jun; 30(1):31-8. PubMed ID: 22153557
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R, Kragballe K, Dam TN, Skov L.
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [Abstract] [Full Text] [Related]

  • 49. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M, Rødevand E, Skomsvoll JF.
    Tidsskr Nor Laegeforen; 2005 Jun 16; 125(12):1664-6. PubMed ID: 15976836
    [Abstract] [Full Text] [Related]

  • 50. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug 16; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec 16; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 54. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, Quinn M, Emery P.
    Arthritis Rheum; 2007 Apr 15; 57(3):448-53. PubMed ID: 17394231
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
    Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M.
    J Rheumatol; 2011 Jul 15; 38(7):1355-62. PubMed ID: 21572156
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P.
    Arthritis Care Res (Hoboken); 2010 Oct 15; 62(10):1362-9. PubMed ID: 20506310
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Ménard JF, Muraine M, Savoye G, Le Loët X, Tharasse C, Vittecoq O.
    Rheumatology (Oxford); 2009 Jul 15; 48(7):761-4. PubMed ID: 19395543
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.